Yahoo
OTC Markets OTCQB - Delayed Quote USD

Marvel Biosciences Corp. (MBCOF)

0.0803 0.0000 (0.00%)
At close: October 30 at 5:00:00 PM EDT
Chart Range Bar
Loading chart for MBCOF
  • Previous Close 0.0803
  • Open 0.0847
  • Bid 0.0768 x 3000000
  • Ask 0.0870 x 6000000
  • Day's Range 0.0847 - 0.0848
  • 52 Week Range 0.0722 - 0.1721
  • Volume 20,000
  • Avg. Volume 7,893
  • Market Cap (intraday) 5.918M
  • Beta (5Y Monthly) 0.37
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date (est.) Nov 26, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.

marvelbiotechnology.com

--

Full Time Employees

July 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

MBCOF
22.77%
S&P/TSX Composite index (^GSPTSE)
12.35%

1-Year Return

MBCOF
47.71%
S&P/TSX Composite index (^GSPTSE)
18.31%

3-Year Return

MBCOF
22.07%
S&P/TSX Composite index (^GSPTSE)
82.41%

5-Year Return

MBCOF
17.77%
S&P/TSX Composite index (^GSPTSE)
69.11%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -172.06%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -1.39M

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    434.8k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -784.89k

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: